Information Provided By:
Fly News Breaks for November 5, 2019
Nov 5, 2019 | 06:17 EDT
Barclays analyst Gena Wang upgraded Halozyme Therapeutics to Equal Weight from Underweight with a price target of $16, down from $17. The analyst believes the HALO-301 failure removed a "major overhang." Strategic refocusing on the core business of Enhanze technology "would further unlock long-term value for the stock," Wang tells investors in a research note.
News For HALO From the Last 2 Days
There are no results for your query HALO